Undisclosed Glycan-Disruption Program

About GlycoTherapeutics

GlycoTherapeutics is an early-stage biotech company developing novel therapies that target glycan-mediated immune suppression to enhance the efficacy of cancer immunotherapies. Founded in 2022 as a university spin-off, the company has secured over €1.5 million in non-dilutive grant funding and is building its scientific and business team. While still in the preclinical research phase, its unique focus on the glycobiology of the tumor microenvironment positions it in a promising niche within the immuno-oncology landscape.

Therapeutic Areas